

Translation from Romanian**Biofarm output number: 249/28.04.2026****CURRENT REPORT****According to F.S.A. Regulations no. 5/2018****Report date: 28.04.2026**

Name of the commercial company: BIOFARM S.A.

Registered office: Bucharest, no. 99 Logofatul Tautu Street, 3rd City District

Telephone no.: 021/301.06.00

Fax no.: 021/316.52.48

Website: www.biofarm.ro

Tax registration number: RO 341563

Order no. with the Trade Register: J1991000199407

Fully paid-up share capital: 98.537.535 lei

The market on which company securities are traded – Bucharest Stock Exchange, BIO symbol

Important event to report:

Biofarm S.A. informs that on **28.04.2026**, at 12.00 o'clock p.m., **the Ordinary General Meeting of Shareholders** of Biofarm S.A. took place, convened in compliance with the Companies Law 31/1990 Republished, Law 297/2004 on the capital market, Law 24/2017 on issuers of financial instruments and market operations, Republished, F.S.A. Regulation No. 5/2018 on issuers of financial instruments and market operations, at the office of Biofarm S.A. from no. 99 Logofatul Tautu Street, 3rd City District, Bucharest.

The Ordinary General Meeting of Shareholders unfold its works at the first convocation.

The convening was published in the Official Gazette of Romania Part IV No. 1844/26.03.2026 and in the newspaper <<Jurnalul National>> No. 2121 (9433) of 26.03.2026.

At the Meeting shareholders registered in the Shareholders' Register attended on the **reference date 17.04.2026**.

From the total of 985,375,350 issued shares, at the OGMS a number of 871,346,524 shares were present and voted by mail, representing 88.4278791833 % from the total of issued shares.

The Ordinary General Meeting of Shareholders is statutory and legally constituted.

The Ordinary General Meeting of Shareholders of the Company Biofarm S.A. decides as follows:

It is hereby approved unanimously, pursuant to Article 129 of Romanian Companies Law No. 31/1990, republished, the appointment of a secretariat for the Ordinary General Meeting of Shareholders, composed of Mrs. ION Zoia Mihaela (shareholder of Biofarm S.A.) – secretary, Mr. CONSTANTIN Valentin Daniel – technical secretary, and Mrs. RUSE Elena Ruxandra – technical secretary.

- 1.** The annual report and the audited individual financial statements for the year ended 31 December 2025 prepared in accordance with IFRS as adopted by the European Union are approved unanimously.



The main indicators for 2025 are:

Total incomes: lei 365,881,131
Total expenses: lei 265,247,921
Turnover: lei 319,334,682
Operating result: lei 105,884,336
Gross profit: lei 114,985,888
Net profit: lei 100,633,210
Total equities: lei 548,348,030
Revaluation reserves: lei 10,622,424
Reserves: lei 23,350,438
Reported result: lei 315,378,390
Total assets: lei 636,872,836

2. The discharge from administration for the period 03.11.2025-31.12.2025 is approved unanimously.

3. The Remuneration Report for the leaders of Biofarm S.A. for the year 2025¹ is approved unanimously.

4. The distribution of the net profit made in 2025 and of the gross dividend of lei 0.042 per share are approved unanimously.

The net profit realized in 2025 is distributed as follows:

Dividends: lei 41.385.765.

Retained earnings: lei 59.247.445.

5. The distribution of dividends starting with the date of **29.05.2026**, which is the payment date - in compliance with the provisions of Art. 87 (2) of Law No. 24/2017 Republished and of Art. 178 (2) from the F.S.A. Regulation No. 5/2018, with bearing by shareholders of distribution expenses, as well as establishing the deadline for keeping the dividends at the shareholders' disposal, for a 3 year period from the date of payment is approved unanimously.

6. The empowerment of the Board of Directors for choosing the payment agent and establishing the dividends distribution procedure, in compliance with the legal provisions in force is approved unanimously.

7. The income and expenses budget for the year of 2026 is approved unanimously.

8. The limits of additional remuneration of the members of the Board of Directors, of the General Manager and of the Deputy General Manager is approved as follows:

a) Approval of a net budget of up to 1% of the profit before tax for rewarding the members of the Board of Directors in connection with the achievement of the 2026 budget, as well as approval of the delegation to the Board of Directors of the authority to allocate such amounts is approved unanimously.

b) Approval of a net bonus for the General Manager in an amount of up to 5 net monthly salaries for achieving the 2026 gross profit target (as compared to the 2026 budget), as well as a variable net bonus of 2% of the amount by which the actual annual gross profit exceeds the budgeted gross profit for 2026. Approval of the delegation to the Board of Directors of the authority to determine the amount of such bonuses within the approved limits, is approved unanimously.

c) Approval of a net bonus for the Deputy General Manager in an amount of up to 5 net monthly salaries for achieving the 2026 gross profit target (as compared to the 2026 budget), as well as approval of the delegation to the Board of Directors of the authority to determine the amount of such bonus within the approved limits is approved with majority.

9. The investment plan for the year 2026 is approved unanimously.

¹ The opinion of shareholders within the general meeting on the remuneration report, resulted following the vote, has a **consultative character**, according to Art. 107 para. (6) of Law No. 24/2017, Republished.



10. The recognition as income of the unclaimed and uncollected dividends related to the financial years 2017, 2018, 2019, 2020, 2021, is approved unanimously.

11. The empowerment of the Board of Directors to identify new opportunities for Company development through the acquisition of local pharmaceutical companies or local brands that would lead to an increase in market share and to the development of the Biofarm products portfolio and/or pharmaceutical companies/international brands for company development at international level, is approved unanimously.

12. The appointment of the external financial auditor, namely the Deloitte Audit S.R.L. company and fixing the duration of his contract for a period of 1 (one) year, are approved unanimously.

13. The date of 14.05.2026 is approved as the registration date in compliance with the provisions of Art. 87 (1) of Law No. 24/2017 Republished, is approved unanimously.

14. The date of 13.05.2026 is approved as the ex date in compliance with the provisions of Art. 176 (1) from the F.S.A. Regulation No. 5/2018 and Art. 2 (2) letter I from the F.S.A. Regulation No. 5/2018, is approved unanimously.

15. The mandating of Mr. Andrei Hrebenciuc – Chairman of the Board of Directors of Biofarm S.A. for signing all the documents issued following the Ordinary General Meeting of Shareholders is approved unanimously.

**CHAIRMAN OF THE BOARD OF DIRECTORS
HREBENCIUC Andrei**